Back
Compare AU
Compare V500 vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Vanguard S&P 500 US Shares Index ETF (V500) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
V500 | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 198 | 71 |
Median incremental investment | $650.00 | $684.93 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,090.83 | $2,487.36 |
Average age group | > 35 | > 35 |
Key Summary
V500 | CURE | |
|---|---|---|
Strategy | V500.AX was created on 2026-03-04 by Vanguard. The fund's investment portfolio concentrates primarily on large cap equity. Vanguard S&P 500 US Shares Index ETF seeks to track the return of the S&P 500 Net Total Return Australian Dollars Index before taking into account fees, expenses and tax. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | NVIDIA Corp (7.83 %) Apple Inc (6.99 %) Microsoft Corp (5.10 %) | Moderna Inc (1.55 %) Apogee Therapeutics Inc (1.45 %) Kymera Therapeutics Inc Ordinary Shares (1.37 %) |
Top 3 industries | Health Care (100.00 %) Other (10.24 %) | |
Top 3 countries | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) | |
Management fee | 0.07 % | 0.45 % |
Key Summary
V500 | CURE | |
|---|---|---|
Issuer | Vanguard | Global X |
Tracking index | S&P 500 | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.07 % | 0.45 % |
Price | $55.94 | $77.73 |
Size | $145.987 million | $53.152 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.15 % | 3.39 % |
Market | ASX | ASX |
First listed date | 03/03/2026 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
V500 | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 198 | 71 |
Median incremental investment | $650.00 | $684.93 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,090.83 | $2,487.36 |
Average age group | > 35 | > 35 |
Pros and Cons
V500 | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
V500 | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Lower distribution yield | Higher distribution yield |